Laboratory Corporation of America: Plasma Detect, PGDx Elio Plasma Focus Dx

Laboratory Corporation of America has launched the Labcorp Plasma Detect and PGDx Elio Plasma Focus Dx tests. Plasma Detect is a blood-based whole-genome sequencing assay that detects circulating tumor DNA to identify the presence of molecular residual disease (MRD) in Stage III colon cancer patients. Labcorp launched the test for research purposes in early-stage colon cancer patients last year. It is now available through an Early Experience Program, after which Labcorp intends to expand its availability more broadly. The PGDx Elio Plasma Focus Dx test is a kitted pan-solid tumor liquid biopsy test intended to aid oncologists in selecting targeted cancer treatments. As an FDA-authorized test kit, the assay allows clinical laboratories and hospitals to retain control over patient specimens and data and returns results in four to five days.